Background: To evaluate the clinical efficacy of Glucagon-Like Peptide-1 (GLP-1) analogues on the blood sugar levels, insulin resistance, islet β-cell function and pre-diabetes of the children.
Methods: Prospective and randomized controlled clinical trial was done on 82 cases of newly diagnosed pre-diabetes in children. First group was comprised of 41 subjects of lifestyle intervention group i.e. control group and the second group were comprised of 41 subject of lifestyle intervention+GLP-1 analogs liraglutide group i.e. observation group. Interventions were done lasted for 3 months. Review of intervention was done at 1 month and at after the 3 months. We carried out the medical examinations at the time when the patient had been diagnosed with prediabetes and after the intervention of 3 months. The medical test examinations includes the Fasting Blood Glucose (FPG), 2 h Postprandial Blood Glucose (2hPG), detection of glycated haemoglobin (HbA1C), Total Cholesterol (TC), Triglyceride (TG), Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), BMI, insulin resistance and the islet cell functions.
Results: After the 1 month of intervention, the observation group showed a better control on FPG and 2hPG compared with the control group (P<0.05). The levels of HbA1C, TC, TG, LDL-C, HDL-C, and BMI of the observation group were statistically better controlled, when compared with the control group after the intervention of 3 months. The insulin resistance index of the observation group was significantly decreased than that of the control group (P<0.05) and the islet function index of the β cell of the observation group showed statistically higher values than that of the control group (P<0.05).
Conclusions: GLP-1 analogs could be a better controller of blood sugar levels, effectively improve lipid profile, body mass, insulin resistance and islet β-cell function. Furthermore, GLP-1 analogs open up a new way to intervene pre-diabetes in children.